Tyme Technologies Inc (OQ:TYME)

Jan 16, 2020 08:00 am ET
TYME and The Joseph Ahmed Foundation Announce First Patient Dosed in Phase II (HopES) Trial Evaluating the Potential Benefits of Oral SM-88 for Patients with High-Risk Sarcomas
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the first sarcoma cancer patient has been dosed at the Sarcoma Oncology Center in the HopES Phase II...
Jan 08, 2020 08:00 am ET
TYME Announces First Patient Dosed in TYME-88-Panc Pivotal Trial to Evaluate SM-88 as Oral Treatment for Patients with Metastatic Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced that the first pancreatic cancer patient has been dosed in Part 2 of the TYME-88-Panc pivotal trial...
Jan 07, 2020 07:20 am ET
Tyme Technologies and Eagle Pharmaceuticals Announce Strategic Collaboration to Advance Innovative Oral SM-88 for the Treatment of Patients with Cancer
Tyme Technologies, Inc. (Nasdaq: TYME) ("TYME"), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), and Eagle Pharmaceuticals, Inc. (Nasdaq: EGRX) (“Eagle”), today announced the formation of a U.S. strategic collaboration focused on the co-promotion of TYME’s lead CMBT candidate oral SM-88 in advanced cancers. CMBTs are proprietary investigational compounds that are believed to disrupt cancer cells’ protein synthesis, leading to a breakdown of the cancer’s key defenses and cell death. In clinical trials, oral SM-88 has demonstrated complete o
Dec 04, 2019 08:00 am ET
Tyme Technologies to Present at the 2019 Cross-Border Healthcare Winter Summit in New York
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 2019 Cross-Border Healthcare Winter Summit on Tuesday, December 10, 2019....
Nov 25, 2019 08:00 am ET
TYME to Ring Nasdaq Opening Bell on November 27 to Honor All Stakeholders Committed to Finding a Cure for Patients with Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced it will ring the Nasdaq Opening Bell on Wednesday, November 27, to honor the many stakeholders who are...
Nov 21, 2019 08:00 am ET
Tyme Technologies to Present at the Evercore ISI HealthCONx Conference 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Evercore ISI HealthCONx Conference 2019 on Wednesday, December 4, 2019....
Nov 07, 2019 08:00 am ET
Tyme Technologies to Present at Jefferies 2019 London Healthcare Conference on November 20-21, 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Jefferies 2019 London Healthcare Conference on Wednesday and Thursday,...
Nov 04, 2019 04:05 pm ET
TYME Presents Business Update and Reports Second Quarter Fiscal 2020 Financial and Operating Results
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced financial and operating results for its fiscal second quarter ended September 30, 2019. During the quarter,...
Oct 17, 2019 04:05 pm ET
TYME Presents Business Update and Announces Second Quarter Fiscal 2020 Conference Call and Preliminary Operational Results
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced preliminary financial and operating results for its fiscal second quarter ended September 30, 2019. During...
Oct 01, 2019 08:00 am ET
TYME Presented Updated Data at ESMO 2019 from SM-88 Phase II Prostate Cancer Study Demonstrating Encouraging Clinical Benefit in Patients with Recurrent Prostate Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism- based therapies (CMBTs™), announced encouraging results from its Phase II trial of oral SM-88 (racemetyrosine) in patients with non-metastatic,...
Sep 30, 2019 08:00 am ET
TYME Presents Supporting Data at ESMO 2019 from TYME-88-Panc Phase II Study Demonstrating Overall Survival Trends, Well Tolerated Safety, and Quality of Life Data in Patients with Advanced Pancreatic
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral monotherapy in...
Sep 25, 2019 08:00 am ET
TYME Launches Pivotal Stage of TYME-88-PANC Trial to Evaluate SM-88 for Third-Line Treatment of Patients with Metastatic Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today announced the start of the pivotal stage of the TYME-88-Panc trial to evaluate the clinical benefits of its lead...
Sep 17, 2019 08:00 am ET
Tyme Technologies to Present at the Ladenburg Thalmann 2019 Healthcare Conference on September 24, 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Ladenburg Thalmann 2019 Healthcare Conference on Tuesday, September 24,...
Sep 09, 2019 08:00 am ET
TYME Presents Positive Circulating Tumor Cell Data from TYME-88-Panc Study in Patients with Advanced Pancreatic Cancer at AACR PANC 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), reported encouraging data on circulating tumor cells (CTCs) and a correlation with decrease in risk of death using...
Sep 04, 2019 08:00 am ET
Tyme Technologies to Present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright on September 9, 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 21st Annual Global Investment Conference Sponsored by H.C. Wainwright in...
Aug 12, 2019 08:00 am ET
TYME Announces Abstracts Selected for Presentation at the European Society of Medical Oncology Congress 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that two abstracts highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in...
Aug 09, 2019 08:00 am ET
Tyme Technologies to Present at BTIG Biotechnology Conference on August 12th, 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the BTIG Biotechnology Conference in New York on August 12th, 2019. In...
Aug 08, 2019 08:00 am ET
TYME Provides Business Update and Reports First Quarter Fiscal 2020 Financial and Operating Results
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today provided a business update and reported its financial and operating results for the first quarter fiscal 2020...
Aug 07, 2019 08:00 am ET
TYME Announces Abstracts Selected for Presentation at the AACR Special Conference on Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that two abstracts highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in...
Aug 01, 2019 08:00 am ET
Tyme Technologies to Present at the 39th Annual Canaccord Genuity Growth Conference on August 7th, 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the 39th Annual Canaccord Genuity Growth Conference in Boston on August 7th,...
Jul 29, 2019 08:00 am ET
TYME Technologies Announces New Collaboration with NYU Langone to Advance TYME’s Cancer Metabolism-Based Therapy, SM-88
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company, announced a new research collaboration with NYU Langone Health to advance the development of innovative treatments for patients with metastatic cancers, including pancreatic...
Jul 08, 2019 08:00 am ET
REMINDER - TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral...
Jul 05, 2019 09:31 am ET
Thinking about buying stock in Aurora Cannabis, Beyond Meat, Karyopharm Therapeutics, Northstar Realty, or Tyme Technologies?
NEW YORK, July 5, 2019 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for ACB, BYND, KPTI, NRE, and TYME....
Jul 05, 2019 08:00 am ET
TYME Presents Updated Data at ESMO GI 2019 from TYME-88-Panc Phase II Study Demonstrating Encouraging Overall Survival Trends in Patients with Advanced Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism based therapies (CMBTs™), announced that its multicenter open-label Phase II TYME-88-Panc study evaluating SM-88 (racemetyrosine) as an oral...
Jun 07, 2019 08:00 am ET
TYME Announces Abstract Selected for Presentation at the European Society for Medical Oncology 21st World Congress on Gastrointestinal Cancer 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that an abstract highlighting clinical data for TYME's lead candidate, oral SM-88 (racemetyrosine), in...
May 29, 2019 07:30 am ET
TYME Provides Business Update and Reports Fourth Quarter and Fiscal Year 2019 Financial and Operating Results
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), today provided a business update and reported its financial and operating results for the fiscal year ended March 31,...
May 28, 2019 08:00 am ET
Tyme Technologies to Present at the Jefferies 2019 Global Healthcare Conference on June 7, 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the Jefferies Global Healthcare Conference in New York on June 7, 2019. The...
May 24, 2019 08:00 am ET
Tyme Technologies To Host a Conference Call for the Fourth Quarter and Fiscal Year 2019 Financial and Operating Results on May 29, 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the company will host a conference call and live webcast on Wednesday, May 29, 2019, at 8:30 A.M. ET to...
May 23, 2019 08:00 am ET
TYME and The Joseph Ahmed Foundation Announce Initiation of the HopES Phase II Trial Evaluating the Potential Benefits of SM-88 for Patients with High-Risk Sarcomas
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced the initiation of the HopES trial conducted in partnership with The Joseph Ahmed Foundation to better...
May 20, 2019 08:00 am ET
TYME Announces Notification of Issuance of U.S. Patent Covering SM-88 Single Agent Treatment for Cancers
Tyme Technologies, Inc.  (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that it has received notification that the United States Patent and Trademark Office (USPTO) intends...
May 09, 2019 08:00 am ET
Tyme Technologies to Participate at the Oppenheimer Oncology Insight Summit on May 16th
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will participate at the Oppenheimer Oncology Insight Summit in New York on Thursday, May 16,...
May 02, 2019 08:00 am ET
Tyme Technologies To Present at BioNJ's 9th Annual BioPartnering Conference on May 8th, 2019
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present a corporate overview for 2019 at the BioNJ 9th Annual BioPartnering Conference...
May 01, 2019 08:00 am ET
Tyme Technologies to Participate at the SunTrust Robinson Humphrey 5th Annual Life Sciences Summit on May 7th
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that management will present at the SunTrust Robinson Humphrey’s 5th Annual Life sciences Summit in New York...
Apr 15, 2019 08:00 am ET
TYME Announces USAN Approval of Generic Name “Racemetyrosine” for SM-88
Tyme Technologies, Inc.  (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced today that the United States Adopted Name (USAN) Council recently granted “racemetyrosine” as the generic...
Apr 08, 2019 08:00 am ET
TYME’s SM-88 First Human Study in Patients with Metastatic Cancer Published in the Journal, Investigational New Drugs
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs™), announced that the results of its first human study, completed as of September 15, 2017 and designed to evaluate the...
Apr 03, 2019 08:00 am ET
TYME Secures Capital to Advance Pivotal Studies of SM-88 in Metastatic Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM), announced the closing of its underwritten registered offering with a group of three existing and one new investors...
Apr 01, 2019 08:00 am ET
TYME Announces Dismissal of Class Action Lawsuit
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTsTM) announced the consolidated class action complaint filed in the United States District Court for the Southern District...
Mar 29, 2019 08:00 am ET
Tyme Technologies Announces Pricing of its $12 Million Registered Offering
Tyme Technologies, Inc. (NASDAQ: TYME) announced today that it has priced a registered offering of 8 million shares of its common stock, par value $0.0001 per share, and warrants to purchase 8 million shares of its common stock at a combined...
Mar 28, 2019 04:58 pm ET
SHAREHOLDER ALERT: VALE TYME UXIN UMC: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 28, 2019 01:57 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME  
Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ: TYME) and certain of its officers.  The class action, filed in United States District Court, Southern District of...
Mar 27, 2019 10:00 am ET
Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE) & Lexicon Pharmaceuticals, Inc. (LXRX)
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 26, 2019 05:02 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VALE, TYME, MHLD and BPI
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 26, 2019 03:15 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of TYME, TAP, KHC and SYNH
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 26, 2019 02:52 pm ET
TYME MARCH 29 DEADLINE: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Tyme Technologies, Inc. – TYME
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Tyme Technologies, Inc. (NASDAQ: TYME) from March 14, 2018 through January 18, 2019, inclusive (the “Class Period”). The lawsuit seeks...
Mar 22, 2019 12:26 pm ET
DEADLINE MONDAY: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ: TYME) for violations of §§10(b) and 20(a) of the Securities...
Mar 21, 2019 03:45 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TYME, SVXY, AMR and MBT
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 21, 2019 03:00 pm ET
Class Action Reminder GSM, TYME & LXRX - Bronstein, Gewirtz & Grossman, LLC
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Mar 20, 2019 09:03 pm ET
Pawar Law Group Reminds Investors of  March 29 Deadline in Securities Class Action Lawsuit Against Tyme Technologies, Inc. – TYME
Pawar Law Group announces that a class action lawsuit has been filed on behalf of shareholders who purchased shares of Tyme Technologies, Inc. (NASDAQ: TYME) from March 14, 2018 through January 18, 2019, inclusive (the “Class Period”). The lawsuit...
Mar 20, 2019 02:48 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tyme Technologies, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ:TYME) of the March 29, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Mar 20, 2019 01:09 pm ET
SHAREHOLDER ALERT: GSM TYME AMR CNDT: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 20, 2019 09:37 am ET
CLASS ACTION UPDATE for TYME, KHC, DPLO and CTL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 19, 2019 04:16 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Tyme Technologies, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ:TYME) of the March 29, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Mar 18, 2019 11:57 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of CORT, TYME, TAP and UMC
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 18, 2019 08:00 am ET
TYME Announces Leadership Team Update
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies, announced a realignment in responsibilities among its leadership team. Effective March 15, 2019, Michael Demurjian retired from...
Mar 16, 2019 07:15 pm ET
EQUITY ALERT: Rosen Law Firm Reminds Tyme Technologies, Inc. Investors of Important Deadline in Securities Class Action Lawsuit – TYME
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tyme Technologies, Inc. (NASDAQ: TYME) from March 14, 2018 through January 18, 2019, inclusive (the “Class Period”) of the important March 29, 2019 lead...
Mar 15, 2019 09:50 pm ET
7-DAY DEADLINE ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ: TYME) for violations of §§10(b) and 20(a) of the Securities...
Mar 15, 2019 11:46 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of TYME, DPLO, CVS and SYNH
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 14, 2019 08:56 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME
Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ: TYME) and certain of its officers. The class action, filed in United States District Court, Southern District of...
Mar 14, 2019 03:00 pm ET
(TYME) Tyme Technologies, Inc. - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder & Final Deadline March 29, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Tyme Technologies, Inc. ("Tyme" or the "Company") (NASDAQ: TYME) and certain of its officers, on behalf of shareholders...
Mar 13, 2019 03:28 pm ET
CLASS ACTION UPDATE for TYME, AVEO, CVS and CTL: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 13, 2019 10:17 am ET
SHAREHOLDER ALERT: MAXR MU TYME TAP: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 12, 2019 06:01 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ARLO, ATVI, MU and TYME
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 12, 2019 04:00 pm ET
CLASS ACTION UPDATE for ARLO, TYME, KHC and SYNH: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 12, 2019 03:43 pm ET
TYME DEADLINE ALERT: Zhang Investor Law Reminds Investors of Deadline in Securities Class Action Lawsuit Against Tyme Technologies, Inc. – TYME
Zhang Investor Law announces the filing of a class action lawsuit on behalf of shareholders who bought shares of Tyme Technologies, Inc. (NASDAQ: TYME) from March 14, 2018 through January 18, 2019, inclusive (the “Class Period”). The lawsuit seeks...
Mar 11, 2019 08:00 am ET
Tyme Technologies To Present at the Oppenheimer 29th Annual Healthcare Conference on March 20, 2019 
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that management will present a corporate overview at the Oppenheimer 29th Annual Healthcare Conference in New York on...
Mar 07, 2019 07:09 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME
Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ: TYME) and certain of its officers. The class action, filed in United States District Court, Southern District of...
Mar 07, 2019 05:40 pm ET
TYME LAWSUIT NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Tyme Technologies, Inc. – TYME
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Tyme Technologies, Inc. (NASDAQ: TYME) from March 14, 2018 through January 18, 2019, inclusive (the...
Mar 07, 2019 05:24 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tyme Technologies, Inc. To Contact The Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ:TYME) of the March 29, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Mar 07, 2019 02:06 pm ET
(TYME) Tyme Technologies, Inc. - Bronstein, Gewirtz & Grossman, LLC Class Action Reminder & Final Deadline March 29, 2019
Attorney Advertising--Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against Tyme Technologies, Inc. ("Tyme" or the "Company") (NASDAQ: TYME) and certain of its officers, on behalf of shareholders...
Mar 07, 2019 11:52 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of MAXR, TYME, VNDA and CVS
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 07, 2019 08:00 am ET
TYME Continues to Expand Pipeline of Cancer Metabolism-Based Therapies to Potentially Benefit Patients with Difficult-to-Treat Cancers
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing cancer metabolism-based therapies (CMBTs), announced the addition of a new pre-clinical development candidate, TYME-18, to the Company’s pipeline of medical...
Mar 06, 2019 10:02 am ET
SHAREHOLDER ALERT: AXGN GSM MU TYME: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Mar 05, 2019 10:29 am ET
CLASS ACTION UPDATE for TYME, SVXY, UXIN and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Mar 04, 2019 11:46 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VALE, TYME and WRCDF, WCAGY
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Mar 01, 2019 11:50 am ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of ZIV, TYME, SVXY and MHLD
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Feb 28, 2019 02:32 pm ET
SHAREHOLDER ALERT:  Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME
Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ:  TYME) and certain of its officers.  The class action, filed in United States District Court, Southern District of...
Feb 28, 2019 12:30 pm ET
SHAREHOLDER ALERT: YRIV GSM MU TYME: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Feb 27, 2019 03:45 pm ET
CLASS ACTION UPDATE for GSM, TYME, MHLD and BRS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 27, 2019 12:19 pm ET
CLASS ACTION UPDATE for PRGO, MKL, TYME and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 26, 2019 04:11 pm ET
CLASS ACTION UPDATE for DBVT, TYME, SVXY and CVS: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 26, 2019 03:27 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 in Tyme Technologies, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ:TYME) of the March 29, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company.
Feb 26, 2019 02:17 pm ET
CLASS ACTION UPDATE for DNKEY, MAXR, TYME and CAG: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 26, 2019 10:41 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of VALE, TYME, BRS and AVP
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 25, 2019 06:21 pm ET
TYME CLASS ACTION NOTICE: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Tyme Technologies, Inc. - TYME
NEW YORK, Feb. 25, 2019 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Tyme Technologies, Inc. (NASDAQ: TYME) from March 14, 2018 through January 18, 2019, inclusive (the "Class Period"). The lawsuit seeks to recover damages for Tyme investors under the federal securities laws....
Feb 25, 2019 05:38 pm ET
CLASS ACTION UPDATE for AXGN, MAXR, TYME and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 25, 2019 02:27 pm ET
CLASS ACTION UPDATE for YOGA, SOGO, GSM and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 25, 2019 11:37 am ET
CLASS ACTION UPDATE for DXC, TYME, GE and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 25, 2019 08:00 am ET
TYME Receives FDA Guidance on Pivotal Trial for SM-88 in Treatment for Advanced Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced that it received design guidance for a registrational trial from the U.S. Food and Drug Administration (FDA) on a drug...
Feb 24, 2019 07:20 pm ET
CLASS ACTION UPDATE for YRCW, AXGN, MAXR and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 24, 2019 01:25 pm ET
CLASS ACTION UPDATE for YRIV, GSM, MU and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 24, 2019 10:50 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of DNKEY, YRCW, DBVT and TYME
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 22, 2019 05:27 pm ET
CLASS ACTION UPDATE for IMMU, GSM, TYME and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 22, 2019 10:34 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ATVI, TYME and WRCDF, WCAGY
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 21, 2019 05:03 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME
Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ: TYME) and certain of its officers. The class action, filed in United States District Court, Southern District of...
Feb 21, 2019 03:41 pm ET
CLASS ACTION UPDATE for DXC, VALE, TYME and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 21, 2019 02:03 pm ET
CLASS ACTION UPDATE for DNKEY, YRIV, TYME and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 21, 2019 10:57 am ET
CLASS ACTION UPDATE for YOGA, ARLO, TYME and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 20, 2019 07:30 pm ET
CLASS ACTION UPDATE for YRIV, ATVI, TYME and UXIN: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 20, 2019 12:04 pm ET
CLASS ACTION UPDATE for ARLO, DBVT, VALE and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 20, 2019 09:52 am ET
CLASS ACTION UPDATE for IMMU, AXGN, ATVI and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 19, 2019 01:25 pm ET
CLASS ACTION UPDATE for VALE, TYME, UXIN and AVP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 19, 2019 11:41 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ATVI, MU, TYME and SVXY
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 19, 2019 10:27 am ET
CLASS ACTION UPDATE for DNKEY, YRCW, ATVI and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 18, 2019 04:00 pm ET
CLASS ACTION UPDATE for ARLO, W, VALE and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 18, 2019 10:07 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ATVI, MU, TYME and SVXY
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 18, 2019 06:00 am ET
CLASS ACTION UPDATE for AXGN, TYME, UXIN and TAP: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 17, 2019 02:05 pm ET
CLASS ACTION UPDATE for IMMU, DBVT, MU and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 17, 2019 11:00 am ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of YRCW, TYME, UXIN and TAP
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 17, 2019 08:04 am ET
CLASS ACTION UPDATE for AXGN, TYME and MHLD: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 15, 2019 03:22 pm ET
TYME EQUITY ALERT: Rosen Law Firm Reminds Tyme Technologies, Inc. Investors of Important Deadline in Securities Class Action Lawsuit Seeking to Recover Investor Losses – TYME
Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Tyme Technologies, Inc. (NASDAQ: TYME) from March 14, 2018 through January 18, 2019, inclusive (the “Class Period”) of the important March 29, 2019 lead plaintiff deadline in the class action. The lawsuit seeks to recover damages for Tyme investors under the federal securities laws.
Feb 15, 2019 01:26 pm ET
CLASS ACTION UPDATE for GSM, MU, TYME and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 15, 2019 12:48 pm ET
INVESTOR ACTION REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the F
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ: TYME) for violations of §§10(b) and 20(a) of the Securities...
Feb 15, 2019 10:15 am ET
CLASS ACTION UPDATE for AGN, ATVI, TYME and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 14, 2019 06:17 pm ET
EQUITY ALERT: Rosen Law Firm Announces Filing of Securities Class Action Lawsuit Against Tyme Technologies, Inc. – TYME
Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of the securities of Tyme Technologies, Inc. (NASDAQ: TYME) from March 14, 2018 through January 18, 2019, inclusive (the “Class Period”). The lawsuit seeks to recover damages for Tyme investors under the federal securities laws.
Feb 14, 2019 04:47 pm ET
CLASS ACTION UPDATE for GS, XRAY, MAXR and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 14, 2019 04:11 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME
Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ:  TYME) and certain of its officers.   The class action, filed in United States District Court, Southern District...
Feb 14, 2019 08:00 am ET
TYME Reports Encouraging SM-88 Clinical Results without Typical Hormone-Related Side Effects in Phase II Study of Patients with Biomarker Recurrent Prostate Cancer
Tyme Technologies, Inc. (NASDAQ:TYME), an emerging biotechnology company developing metabolic-based cancer therapies, announced encouraging preliminary results from an ongoing Phase II trial of SM-88 in patients with non-metastatic,...
Feb 13, 2019 06:00 pm ET
CLASS ACTION UPDATE for YOGA, NVDA, AXGN and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 13, 2019 01:35 pm ET
CLASS ACTION UPDATE for ARLO, XRAY, GSM and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 13, 2019 12:00 pm ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Arlo Technologies, Inc. (ARLO), Micron Technology, Inc. (MU) and Ferroglobe PLC (GSM) & Tyme Technologie
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 13, 2019 10:10 am ET
CLASS ACTION UPDATE for GS, MAXR, ATVI and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 12, 2019 06:09 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors who Suffered Losses Exceeding $50,000 in Tyme Technologies, Inc. to Contact the Firm
Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ:TYME) of the March 29, 2019 deadline to seek the role of lead plaintiff in a federal securities class...
Feb 12, 2019 01:56 pm ET
CLASS ACTION UPDATE for MAXR, GSM, MU and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 11, 2019 04:31 pm ET
CLASS ACTION UPDATE for TDOC, ARLO, XRAY and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 11, 2019 01:44 pm ET
CLASS ACTION UPDATE for YRIV, VALE, TYME and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 11, 2019 11:13 am ET
CLASS ACTION UPDATE for ARLO, VALE, TYME and GE: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 11, 2019 07:30 am ET
TYME Reports Third Quarter Fiscal 2019 Financial and Operating Results
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies, today reported its financial and operating results and provided a business update for the fiscal quarter ended December 31, 2018....
Feb 08, 2019 01:02 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of YRIV, ALKS, MAXR and TYME
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 08, 2019 10:33 am ET
CLASS ACTION UPDATE for PRGO, AXGN, AGN and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 07, 2019 05:22 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Reminds Shareholders with Losses on their Investment in Tyme Technologies, Inc. of Class Action Lawsuit and Upcoming Deadline – TYME
Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ:  TYME) and certain of its officers.   The class action, filed in United States District Court, Southern District...
Feb 07, 2019 04:20 pm ET
CLASS ACTION UPDATE for DNKEY, NVDA, DXC and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 07, 2019 12:21 pm ET
CLASS ACTION UPDATE for DBVT, MKL, VALE and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 07, 2019 11:02 am ET
CLASS ACTION UPDATE for WBT, DBVT, ASTE and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 07, 2019 10:00 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Tyme Technologies, Inc. (TYME), Vale S.A. (VALE), Lexicon Pharmaceuticals, Inc. (LXRX) & ProShares Short
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may...
Feb 06, 2019 02:20 pm ET
CLASS ACTION UPDATE for WBT, NSANY, VALE and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 06, 2019 11:42 am ET
INVESTOR ACTION ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ: TYME) for violations of §§10(b) and 20(a) of the Securities...
Feb 05, 2019 08:12 pm ET
CLASS ACTION UPDATE for TS, IMMU, GSM and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Feb 05, 2019 05:30 pm ET
LEAD PLAINTIFF DEADLINE ALERT: Faruqi & Faruqi, LLP Encourages Investors Who Suffered Losses Exceeding $50,000 In Tyme Technologies, Inc. To Contact The Firm
NEW YORK, Feb. 5, 2019 /PRNewswire/ -- Faruqi & Faruqi, LLP, a leading national securities law firm, reminds investors in Tyme Technologies, Inc. ("Tyme" or the "Company") (NASDAQ:TYME) of the March 29, 2019 deadline to seek the role of lead plaintiff in a federal securities class action that has been filed against the Company. ...
Feb 05, 2019 03:54 pm ET
IMPORTANT INVESTOR REMINDER: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact th
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ:
Feb 05, 2019 02:00 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of ASTE, VALE, TYME and SVXY
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 04, 2019 07:46 pm ET
SHAREHOLDER ALERT: ATVI VALE TYME ARLO: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Feb 04, 2019 06:16 pm ET
IMPORTANT INVESTOR ALERT: The Schall Law Firm Announces the Filing of a Class Action Lawsuit Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $500,000 to Contact the F
The Schall Law Firm, a national shareholder rights litigation firm, announces the filing of a class action lawsuit against Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ:
Feb 04, 2019 12:00 pm ET
FILING DEADLINE--Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of MKL, MAXR, ATVI and TYME
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Feb 01, 2019 05:07 pm ET
SHAREHOLDER ALERT: ATVI MU VALE TYME: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Feb 01, 2019 01:11 pm ET
ONGOING INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ: TYME) for violations of §§10(b) and 20(a) of the...
Feb 01, 2019 12:03 pm ET
CLASS ACTION UPDATE for MU, VALE and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jan 31, 2019 08:07 pm ET
SHAREHOLDER ALERT: DBVT MU VALE TYME: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jan 31, 2019 02:00 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of YRCW, AGN, VALE and TYME
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jan 31, 2019 01:51 pm ET
INVESTIGATION REMINDER: The Schall Law Firm Announces it is Investigating Claims Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ:
Jan 31, 2019 12:51 pm ET
Robbins Arroyo LLP: Tyme Technologies Inc. (TYME) Misled Shareholders According to a Recently Filed Class Action
Shareholder rights law firm Robbins Arroyo LLP announces that purchasers of Tyme Technologies Inc. (NASDAQ: TYME) filed a class action complaint against the company for alleged violations of the Securities and Exchange Act of 1934 between March 14, 2018 and January 18, 2019. Tyme is a clinical-stage b
Jan 31, 2019 07:07 am ET
CLASS ACTION UPDATE for DBVT, VALE, TYME and SVXY: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jan 30, 2019 09:34 pm ET
INVESTIGATION ALERT: The Schall Law Firm Announces it is Investigating Claims Against Tyme Technologies, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
The Schall Law Firm, a national shareholder rights litigation firm, announces that it is investigating claims on behalf of investors of Tyme Technologies, Inc. (“Tyme” or “the Company”) (NASDAQ:
Jan 30, 2019 07:31 pm ET
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation on Behalf of Tyme Technologies, Inc. Investors (TYME)
Law Offices of Howard G. Smith announces an investigation on behalf of Tyme Technologies, Inc. investors (“Tyme” or the “Company”) (NASDAQ: TYME) concerning the Company and its officers’ possible violations of federal securities laws.
Jan 30, 2019 04:07 pm ET
CLASS ACTION UPDATE for XPO, IMMU, MAXR and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jan 30, 2019 02:15 pm ET
SHAREHOLDER ALERT: LOMA XRAY MU TYME: The Law Offices of Vincent Wong Reminds Investors of Important Class Action Deadlines
The Law Offices of Vincent Wong announce that class actions have commenced on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jan 29, 2019 08:11 pm ET
Kuznicki Law PLLC Announces Class Actions on Behalf of Shareholders of GSM, MU, VALE and TYME
The securities litigation law firm of Kuznicki Law PLLC issues the following notice on behalf of shareholders of the following publicly traded companies. Shareholders who purchased shares in these companies during the dates listed below are...
Jan 29, 2019 05:19 pm ET
Federman & Sherwood Announces Filing of Securities Class Action Lawsuit Against Tyme Technologies, Inc.
Federman & Sherwood announces that on January 28, 2019, a class action lawsuit was filed in the United States District Court for the Southern District of New York against Tyme Technologies, Inc. (NASDAQ: TYME). The complaint alleges violations of federal securities laws, Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5, including allegations of issuing a series of material or false misrepresentations to the market which had the effect of artificially inflating the market price during the Class Period, which is March
Jan 29, 2019 04:11 pm ET
The Klein Law Firm Reminds Investors of Class Actions on Behalf of Shareholders of GS, APHA, VALE and TYME
The Klein Law Firm announces that class action complaints have been filed on behalf of shareholders of the following companies. If you suffered a loss you have until the lead plaintiff deadline to request that the court appoint you as lead...
Jan 29, 2019 02:00 pm ET
CLASS ACTION UPDATE for NVDA, AGN, VALE and TYME: Levi & Korsinsky, LLP Reminds Investors of Class Actions on Behalf of Shareholders
Levi & Korsinsky, LLP announces that class action lawsuits have commenced on behalf of shareholders of the following publicly-traded companies. Shareholders interested in serving as lead plaintiff have until the deadlines listed to petition the...
Jan 29, 2019 10:00 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action Against Tyme Technologies, Inc. (TYME) & Lead Plaintiff Deadline: March 29, 2019
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC notifies investors that a class action lawsuit has been filed against Tyme Technologies, Inc. ("Tyme" or the "Company") (NASDAQ: TYME) and certain of its officers, on behalf of shareholders...
Jan 28, 2019 08:44 pm ET
Pomerantz Law Firm Announces the Filing of a Class Action against Tyme Technologies, Inc. and Certain Officers – TYME
Pomerantz LLP announces that a class action lawsuit has been filed against Tyme Technologies, Inc. (“Tyme” or the “Company”) (NASDAQ: TYME) and certain of its officers. The class action, filed in United States District Court, Southern District of...
Jan 24, 2019 01:53 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyme Technologies, Inc. - TYME
Pomerantz LLP is investigating claims on behalf of investors of  Tyme Technologies, Inc. (“Tyme or the “Company”) (NASDAQ:  TYME).   Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Jan 22, 2019 07:44 pm ET
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Tyme Technologies, Inc. - TYME
NEW YORK, Jan. 22, 2019 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Tyme Technologies, Inc. ("Tyme or the "Company") (NASDAQ:  TYME). Such investors are advised to contact Robert S. Willoughby at rswilloughby@pomlaw.com or 888-476-6529, ext. 9980....
Jan 22, 2019 11:14 am ET
SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Tyme Technologies, Inc. (TYME) 
Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Tyme Technologies, Inc. ("Tyme" or the "Company") (NASDAQ: TYME). Such investors are encouraged to obtain additional information...
Jan 18, 2019 08:00 am ET
TYME’s Novel Metabolic-Based Cancer Therapy, SM-88, Improves Survival in Phase II Study of Patients with Advanced Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ: TYME), an emerging biotechnology company developing metabolic-based cancer therapies announces that an open label phase II clinical trial evaluating SM-88 as a monotherapy in end-stage patients with advanced...
Jan 15, 2019 08:00 am ET
Tyme Schedules Conference Call to Discuss SM-88 Preliminary Phase II Pancreatic Cancer Data on Friday, January 18th
Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage oncology biotechnology company developing metabolically-based cancer therapeutics, today announced that its management team will hold a conference call with analysts and investors at 9 AM EST...
Jan 04, 2019 08:00 am ET
Tyme Announces the Presentation of SM-88 Data at the 2019 ASCO Genitourinary Cancers Symposium
Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will present clinical data from the Company’s lead candidate, SM-88, at the 2019 ASCO Genitourinary...
Nov 26, 2018 04:01 pm ET
Tyme Technologies, Inc. to Present at the Piper Jaffray Healthcare Conference on November 28th
Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced that it will be featured as a presenting company at the Piper Jaffray Healthcare...
Nov 26, 2018 08:00 am ET
Tyme Announces the Presentation of Clinical Abstracts at the 2019 Gastrointestinal Cancers Symposium
Tyme Technologies, Inc. (NASDAQ: TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will present clinical data from the Company’s lead candidate SM-88 at the 2019 Gastrointestinal...
Nov 20, 2018 04:45 pm ET
Tyme Technologies, Inc. to Present at the Evercore ISI, HealthconX Conference on November 27th
Tyme Technologies, Inc. (NASDAQ:TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced that it will be featured as a presenting company at the Evercore ISI, HealthconX...
Nov 08, 2018 04:30 pm ET
Tyme, Inc. to Present at the Stifel 2018 Healthcare Conference on November 13th
Tyme Technologies, Inc. (NASDAQ: TYME), a clinical stage biotechnology company developing cancer therapeutics for pancreatic, prostate and sarcoma tumors, today announced that it will be featured as a presenting company at the Stifel 2018...
Nov 05, 2018 08:33 am ET
Tyme Provides Clinical and Corporate Update for Fiscal 2Q 2019
Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal quarter ended September 30, 2018. The Company’s lead...
Oct 15, 2018 08:00 am ET
Tyme Appoints Former Kite and Celgene Executive, Michele Korfin, as Chief Commercial Officer
Tyme Technologies Inc, (Nasdaq: TYME), a clinical stage biotechnology company developing cancer therapeutics to address multiple tumor types, today announced the appointment of former Kite Pharma and Celgene executive, Michele Korfin as the...
Oct 10, 2018 06:00 am ET
Tyme’s SM-88 to be included in Pancreatic Cancer Action Network’s (PanCAN’s) Novel “Precision Promise(SM)” Adaptive Phase II/III Pancreatic Cancer Trial Platform
Tyme Technologies, Inc. (NASDAQ: TYME) announced today an agreement to include SM-88 as an experimental arm in the novel Precision Promise adaptive Phase II/III trial platform sponsored by PanCAN. The objective of Precision Promise is to expedite...
Sep 27, 2018 08:00 am ET
Tyme Technologies, Inc. and the Joseph Ahmed Foundation Announce Planned Trial for SM-88 in Ewing’s Sarcoma
Tyme Technologies, Inc. (NASDAQ:TYME) today announced that JAF will provide funding and patient support for an investigator-initiated Phase II trial of SM-88 in patients with previously treated metastatic Ewing’s sarcoma.  During our compassionate...
Sep 18, 2018 08:00 am ET
Tyme Appoints Accomplished Healthcare Executive Douglas A. Michels to Board of Directors
Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of Douglas A. Michels to the Company’s board of directors, effective October 1, 2018. Mr. Michels, 62,...
Sep 11, 2018 08:00 am ET
Danforth Advisors Names Robert Dickey IV Managing Director, Mid Atlantic Region
Danforth Advisors, LLC, specialists in accounting, finance support and strategy for life science and healthcare companies, today announced additional regional leadership and support with the appointment of Robert Dickey IV as Managing Director, Mid...
Sep 05, 2018 08:00 am ET
Tyme Exceeds Enrollment Expectations for the Phase II Trial of SM-88 in Pancreatic Cancer
Tyme Technologies, Inc. (NASDAQ:TYME), today announced that the number of currently consented or randomized subjects has exceeded the enrollment target for the Stage 1 dose selection portion of the Company’s Phase II trial in metastatic pancreatic...
Aug 27, 2018 08:00 am ET
Tyme Technologies, Inc. to Present at the Rodman & Renshaw 20th Annual Global Investment Conference
Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced that it will be featured as a presenting company at the Rodman Renshaw 20th Annual Global Investment...
Jul 30, 2018 07:30 am ET
Tyme Technologies Provides Clinical and Corporate Update for Fiscal 1Q 2019
Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal quarter ended June 30, 2018. The Company’s lead clinical...
Jun 25, 2018 08:00 am ET
Tyme Technologies, Inc. Set to Join Russell 3000® Index
Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced it is set to join the Russell 3000® Index at the conclusion of the Russell U.S. Indexes annual...
Jun 12, 2018 08:00 am ET
Tyme Releases Detailed Data and Analyses with SM-88 From the First Human Study and Compassionate Use Programs
Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today release detailed patient data and analyses from both the First Human Study (FHS) and Compassionate Use Program of SM-88 in...
May 30, 2018 07:30 am ET
Tyme Appoints Pharma Executive Don DeGolyer to Board of Directors
Tyme, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced the appointment of Don DeGolyer to the Company’s board of directors. Mr. DeGolyer is the founder, Chief Executive Officer, and a...
May 17, 2018 08:00 am ET
Tyme Announces Five Clinical Abstracts at the 2018 ASCO Annual Meeting
Tyme, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced the availability of additional clinical data from the Company’s lead candidate SM-88 being presented in five abstracts...
Apr 09, 2018 07:00 am ET
Tyme Provides Clinical and Corporate Update for Fiscal Year End 2018
NEW YORK, April 09, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company developing metabolically-based cancer therapeutics, today announced a clinical and corporate update for the fiscal year ended March 31, 2018. The Company’s lead...
Apr 06, 2018 08:00 am ET
Tyme and JAF Announce Sarcoma Treatment Collaboration
NEW YORK, April 06, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage oncology company, today announced that it is collaborating with The Joseph Ahmed Foundation (“JAF”) to provide treatment for metastatic sarcomas. The collaboration will focus...
Mar 29, 2018 08:00 am ET
Tyme Technologies, Inc. Announces Participation at the H.C. Wainwright Annual Global Life Sciences Conference in Monte Carlo, Monaco on April 8-10, 2018
NEW YORK, March 29, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that it will be featured as a presenting company at the H. C. Wainwright Annual Global Life Sciences Conference.  The conference...
Mar 27, 2018 08:00 am ET
Tyme Announces First Site Open for its Phase II Trial with SM-88 in Pancreatic Cancer
NEW YORK, March 27, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (“Tyme” or the “Company”) announced today that the first site for the Phase II clinical trial evaluating SM-88 therapy for metastatic pancreatic cancer is open and additional...
Mar 14, 2018 08:00 am ET
FDA Acceptance of IND for Tyme to Begin Phase II Trial in Pancreatic Cancer
Initial Clinical Sites Expected to Open Over the Coming Weeks
Mar 08, 2018 08:00 am ET
Tyme Technologies Announces Closing of Public Offering of Common Stock
Proceeds Allow SM-88 Advancement to Planned Clinical Milestones
Mar 01, 2018 09:46 pm ET
Tyme Technologies Announces Pricing of its Offering of 9 Million Shares of Common Stock
NEW YORK, March 01, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (the “Company”) announced today that it has priced its underwritten public offering of 9 million shares of its common stock, par value $0.0001 per share at...
Feb 26, 2018 04:01 pm ET
Tyme Technologies Announces Offering of Common Stock
NEW YORK, Feb. 26, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME) (the “Company”), a clinical-stage biotechnology company developing cancer therapeutics, today announced that it had commenced an underwritten public offering of up to 12 million shares of...
Feb 21, 2018 09:00 am ET
Tyme Technologies Appoints Tommy G. Thompson to Board of Directors
Company Prepares to Initiate Phase II Trial for Pancreatic Cancer Therapy
Feb 13, 2018 08:00 am ET
Tyme to Present at RBC Capital Markets 2018 Global Healthcare Conference
NEW YORK, Feb. 13, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that company management will present at the RBC Capital Markets 2018 Global Healthcare Conference, to be held...
Feb 08, 2018 10:00 am ET
Tyme Announces Interim Phase II Safety and Efficacy Data for SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium
SAN FRANCISCO, Feb. 08, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced efficacy and safety data from an ongoing Phase II trial of SM-88 in patients with non-metastatic, biochemical-recurrent...
Feb 07, 2018 09:44 am ET
Tyme Provides Clinical and Corporate Update for Fiscal Third Quarter 2017
NEW YORK, Feb. 07, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced a clinical and corporate update for the fiscal third quarter ended December 31, 2017. The Company’s lead...
Jan 30, 2018 08:00 am ET
Tyme Announces Prostate Cancer Collaboration with Dr. Mack Roach III of UCSF
NEW YORK, Jan. 30, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (NASDAQ:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that Mack Roach III, M.D., FASTRO, FACR, Professor of Radiation Oncology, Medical Oncology and Urology at the...
Jan 19, 2018 11:46 am ET
Tyme Announces Positive Efficacy Data for SM-88 in Pancreatic Cancer at 2018 ASCO Gastrointestinal Cancers Symposium
SAN FRANCISCO, Jan. 19, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced efficacy and safety data for SM-88 in patients with advanced metastatic or recurrent pancreatic cancer. The data...
Jan 04, 2018 08:00 am ET
Tyme Announces Presentation of Clinical Data on SM-88 in Prostate Cancer at 2018 ASCO Genitourinary Cancers Symposium
NEW YORK, Jan. 04, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies, Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that data from the ongoing Phase II clinical trial of its lead therapy SM-88 in patients with...
Jan 03, 2018 07:00 am ET
Tyme to Present at 36th Annual J.P. Morgan Healthcare Conference
NEW YORK, Jan. 03, 2018 (GLOBE NEWSWIRE) -- Tyme Technologies Inc. (Nasdaq:TYME), a clinical-stage biotechnology company developing cancer therapeutics, today announced that management will present at the 36th Annual J.P. Morgan Healthcare Conference, to be held Jan. 8-11,...